Catalent   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Somerset NJ United States (2007)
Status: Acquired by Micron Technologies (2014)

Organization Overview

First Clinical Trial
2013
NCT02009410
First Marketed Drug
2007
valproic acid (depakene)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Catalent | CATALENT

Active Ingredients

Marketed Drugs (3)

cetirizine (zyrtec) (2020)

naproxen (naprosyn) (2019)

valproic acid (depakene) (1991)

Drugs in Phase 4 Trials (1)

pancrelipase (creon) (1 trial)

Drugs in Phase 3 Trials (2)

Key: Catalent (1) Acquired (1)

progesterone (progestasert) (4 trials)

s-adenosyl methionine (1 trial)

Drugs in Phase 2 Trials (1)

Key: Catalent (0) Acquired (1)

lidocaine (xylocaine) (2 trials)

Drugs in Phase 1 Trials (1)

medi1341 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholestasis (Phase 3)

Cholestasis, Intrahepatic (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Exocrine Pancreatic Insufficiency (Phase 4)

Liver Diseases (Phase 3)

Liver Diseases, Alcoholic (Phase 3)

Parkinson Disease (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 5